Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (376 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-02-09. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: cancerpaintumorscellradiation
  Phrases that lowered it: patients whopatients withlesionhave receivedplatinum
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports with a death: 28.8% (raises risk) · Drug's FDA history
• Sponsor's past trials: 386 (lowers risk) · Sponsor's track record
• Sponsor's past termination rate: 8.0% (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 220 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: government (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 98.5% (raises risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Responsible party: sponsor (lowers risk) · Design
• Disease area, dermatology: No (lowers risk) · Disease area
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports before start: 4812 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer NCT01716715 · started 2012 · scored riskier than 26% of active trials completed
• Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer NCT00886691 · started 2010 · scored riskier than 25% of active trials completed
• Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT02315430 · started 2015 · scored riskier than 60% of active trials completed
• Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy NCT00693992 · started 2008 · scored riskier than 63% of active trials completed
• Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer NCT00698815 · started 2008 · scored riskier than 44% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.